OncoCyte Corporation

LSE:0KCC Stock Report

Market Cap: US$41.0m

OncoCyte Valuation

Is 0KCC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0KCC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0KCC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0KCC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0KCC?

Key metric: As 0KCC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0KCC. This is calculated by dividing 0KCC's market cap by their current book value.
What is 0KCC's PB Ratio?
PB Ratio4.2x
BookUS$9.71m
Market CapUS$40.99m

Price to Book Ratio vs Peers

How does 0KCC's PB Ratio compare to its peers?

The above table shows the PB ratio for 0KCC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.8x
ETX e-therapeutics
1.9xn/aUK£52.6m
TRX Tissue Regenix Group
1.7x170.8%UK£41.0m
HEMO Hemogenyx Pharmaceuticals
5.4xn/aUK£16.5m
OPTI OptiBiotix Health
2.3xn/aUK£16.7m
0KCC OncoCyte
4.2x31.0%US$41.0m

Price-To-Book vs Peers: 0KCC is expensive based on its Price-To-Book Ratio (4.2x) compared to the peer average (2.8x).

Price to Book Ratio vs Industry

How does 0KCC's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.5x101.0%US$3.60m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
0KCC 4.2xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0KCC is expensive based on its Price-To-Book Ratio (4.2x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0KCC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0KCC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0KCC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0KCC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.11
US$4.13
+96.0%
3.0%US$4.25US$4.00n/a2
Nov ’25US$3.09
US$4.13
+33.5%
3.0%US$4.25US$4.00n/a2
Oct ’25n/a
US$4.13
0%
3.0%US$4.25US$4.00n/a2
Sep ’25n/a
US$4.42
0%
9.6%US$5.00US$4.00n/a3
Aug ’25US$3.14
US$4.58
+46.0%
6.8%US$5.00US$4.25n/a3
Jul ’25US$2.82
US$4.42
+56.5%
9.6%US$5.00US$4.00n/a3
Jun ’25US$2.90
US$4.06
+40.1%
17.6%US$5.00US$3.00n/a4
May ’25US$2.50
US$4.06
+62.5%
17.6%US$5.00US$3.00n/a4
Apr ’25n/a
US$3.53
0%
11.6%US$4.00US$3.00n/a3
Mar ’25US$2.97
US$3.53
+19.0%
11.6%US$4.00US$3.00n/a3
Feb ’25US$2.92
US$3.90
+33.6%
18.7%US$5.00US$3.00n/a4
Jan ’25US$2.53
US$3.90
+54.0%
18.7%US$5.00US$3.00n/a4
Dec ’24US$3.63
US$3.90
+7.6%
18.7%US$5.00US$3.00n/a4
Nov ’24n/a
US$4.19
0%
12.9%US$5.00US$3.50US$3.094
Oct ’24n/a
US$4.19
0%
12.9%US$5.00US$3.50n/a4
Sep ’24n/a
US$4.19
0%
12.9%US$5.00US$3.50n/a4
Aug ’24US$3.96
US$7.00
+76.9%
30.3%US$9.00US$4.00US$3.144
Jul ’24US$4.39
US$7.00
+59.5%
30.3%US$9.00US$4.00US$2.824
Jun ’24US$4.38
US$7.00
+59.7%
30.3%US$9.00US$4.00US$2.904
May ’24US$5.09
US$9.00
+77.0%
7.9%US$10.00US$8.00US$2.504
Apr ’24n/a
US$16.50
0%
48.8%US$28.00US$8.00n/a4
Mar ’24n/a
US$16.50
0%
48.8%US$28.00US$8.00US$2.974
Feb ’24n/a
US$16.50
0%
48.8%US$28.00US$8.00US$2.924
Jan ’24US$6.10
US$19.00
+211.5%
33.7%US$28.00US$10.00US$2.534
Dec ’23n/a
US$25.20
0%
73.9%US$60.00US$10.00US$3.635
Nov ’23n/a
US$46.67
0%
43.0%US$80.00US$18.00n/a6

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$753.98

7D

0.6%

1Y

-8.0%

Formycon

€857.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€50.00

7D

7.5%

1Y

-24.1%

hVIVO

UK£144.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-6.1%

1Y

3.4%